Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$68.48
0.0%		$76.54
$40.00
▼
$99.50
$2.63B0.97534,558 shs450,834 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$23.32
+3.3%		$26.79
$21.02
▼
$42.21
$2.70B0.091.57 million shs2.87 million shs
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$25.67
+1.0%		$25.32
$8.19
▼
$28.23
$2.64B1.81.27 million shs1.51 million shs
Verastem, Inc. stock logo
VSTM
Verastem
$8.37
+4.8%		$6.90
$3.43
▼
$10.82
$723.60M0.322.25 million shs3.06 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-0.01%+1.75%-14.20%-2.82%+11.37%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
+3.28%+10.21%-16.33%-28.48%-13.79%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
+1.02%+3.38%-3.93%+33.01%+204.51%
Verastem, Inc. stock logo
VSTM
Verastem
+4.76%+14.03%+21.48%+117.40%-8.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$68.48
0.0%		$76.54
$40.00
▼
$99.50
$2.63B0.97534,558 shs450,834 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$23.32
+3.3%		$26.79
$21.02
▼
$42.21
$2.70B0.091.57 million shs2.87 million shs
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$25.67
+1.0%		$25.32
$8.19
▼
$28.23
$2.64B1.81.27 million shs1.51 million shs
Verastem, Inc. stock logo
VSTM
Verastem
$8.37
+4.8%		$6.90
$3.43
▼
$10.82
$723.60M0.322.25 million shs3.06 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-0.01%+1.75%-14.20%-2.82%+11.37%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
+3.28%+10.21%-16.33%-28.48%-13.79%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
+1.02%+3.38%-3.93%+33.01%+204.51%
Verastem, Inc. stock logo
VSTM
Verastem
+4.76%+14.03%+21.48%+117.40%-8.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2.77
Moderate Buy$110.1860.90% Upside
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.85
Moderate Buy$49.73113.24% Upside
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
2.80
Moderate Buy$34.2133.29% Upside
Verastem, Inc. stock logo
VSTM
Verastem
2.82
Moderate Buy$13.8365.27% Upside

Current Analyst Ratings Breakdown

Latest VSTM, NAMS, IRON, and NRIX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2026
Verastem, Inc. stock logo
VSTM
Verastem
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
9/16/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$79.00 ➝ $86.00
9/11/2026
Verastem, Inc. stock logo
VSTM
Verastem
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$18.00
9/11/2026
Verastem, Inc. stock logo
VSTM
Verastem
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$18.00
9/10/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
9/10/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/10/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$128.00
9/10/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$100.00
9/8/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$52.00
9/4/2026
Verastem, Inc. stock logo
VSTM
Verastem
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/2/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$88.00 ➝ $100.00
(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/A$19.52 per shareN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$22.50M123.90N/AN/A$5.97 per share3.91
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$83.98M31.72N/AN/A$5.29 per share4.85
Verastem, Inc. stock logo
VSTM
Verastem
$30.91M24.52N/AN/A$0.74 per share11.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$212.18M-$6.58N/AN/AN/AN/A-37.17%-33.65%11/5/2026 (Estimated)
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$203.82M-$2.16N/AN/AN/A-3,644.21%-34.81%-31.50%11/4/2026 (Estimated)
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$264.46M-$3.45N/AN/AN/A-928.44%-76.09%-57.31%10/8/2026 (Estimated)
Verastem, Inc. stock logo
VSTM
Verastem
-$209.47M-$2.66N/AN/AN/A-231.59%-467.49%-94.54%11/3/2026 (Estimated)

Latest VSTM, NAMS, IRON, and NRIX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/8/2026Q3 2026
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$0.6009N/AN/AN/A$24.35 millionN/A
8/6/2026Q2 2026
Verastem, Inc. stock logo
VSTM
Verastem
-$0.4305-$0.35+$0.0805-$0.35$22.88 million$40.08 million
8/5/2026Q2 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.4819-$0.52-$0.0381-$0.52$2.83 million$3.70 million
7/30/2026Q2 2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$1.71-$1.54+$0.17-$1.54$1.00 millionN/A
7/9/2026Q2 2026
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$0.73-$0.81-$0.08-$0.81$15.29 million$9.04 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/AN/AN/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.09
24.14
24.14
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
9.03
9.03
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A
6.34
6.34
Verastem, Inc. stock logo
VSTM
Verastem
1.48
2.25
2.22

Institutional Ownership

CompanyInstitutional Ownership
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
83.70%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A
Verastem, Inc. stock logo
VSTM
Verastem
88.37%

Insider Ownership

CompanyInsider Ownership
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3.76%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
12.74%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
6.70%
Verastem, Inc. stock logo
VSTM
Verastem
1.94%
CompanyEmployeesShares OutstandingFree FloatOptionable
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
16538.39 million36.95 millionNot Optionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
100119.54 million104.31 millionOptionable
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
357103.78 million96.83 millionOptionable
Verastem, Inc. stock logo
VSTM
Verastem
10290.56 million88.81 millionOptionable

Recent News About These Companies

Verastem (NASDAQ:VSTM) Shares Up 7.1% - Still a Buy?
September 22 at 11:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-verastem-nasdaq-vstm-shares-up-71-still-a-buy-2026-09-22/
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright
September 21 at 11:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-verastem-highlights-ovarian-cancer-launch-kras-g12d-program-at-hc-wainwright-2026-09-21/
Verastem, Inc. (NASDAQ:VSTM) Given Average Recommendation of "Moderate Buy" by Analysts
September 21 at 2:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31035703
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of "Moderate Buy" by Brokerages
September 21 at 2:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-verastem-inc-nasdaq-vstm-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-09-21/
Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says
September 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/verastem-apos-shares-not-fully-145119260.html
Wolfe Research Begins Coverage on Verastem (NASDAQ:VSTM)
September 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031952
Wall Street Zen Downgrades Verastem (NASDAQ:VSTM) to Sell
September 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031677
Verastem (NASDAQ:VSTM) Downgraded by Wall Street Zen to "Sell"
September 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-verastem-nasdaq-vstm-downgraded-by-wall-street-zen-to-sell-2026-09-19/
RBC Capital Keeps Their Buy Rating on Verastem (VSTM)
September 18, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VSTM/pressreleases/3735100/rbc-capital-keeps-their-buy-rating-on-verastem-vstm/
Verastem (NASDAQ:VSTM) Coverage Initiated by Analysts at Wolfe Research
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-verastem-nasdaq-vstm-coverage-initiated-by-analysts-at-wolfe-research-2026-09-17/
H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)
September 14, 2026  |  streetinsider.comhttps://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Verastem+%28VSTM%29/27055420.html
Verastem (NASDAQ:VSTM) Earns Buy Rating from BTIG Research
September 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31019842
Verastem (NASDAQ:VSTM) Earns "Buy" Rating from HC Wainwright
September 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31019839
Bank of New York Mellon Corp Makes New Investment in Verastem, Inc. $VSTM
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-makes-new-investment-in-verastem-inc-vstm-2026-09-12/
Verastem's (VSTM) "Buy" Rating Reiterated at HC Wainwright
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-verastems-vstm-buy-rating-reiterated-at-hc-wainwright-2026-09-11/
Verastem: Avutometinib Plus Defactinib Data De-Risk Efficacy Thesis; Buy Rating Reiterated With Unchanged $18 Price Target
September 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/verastem-avutometinib-plus-defactinib-data-de-risk-efficacy-thesis-buy-rating-reiterated-with-unchanged-18-price-target-ratings-news?utm_source=marketbeat.com&utm_medium=referral
BTIG Research Reaffirms "Buy" Rating for Verastem (NASDAQ:VSTM)
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-btig-research-reaffirms-buy-rating-for-verastem-nasdaq-vstm-2026-09-11/
Opaleye Management Inc. Purchases New Position in Verastem, Inc. $VSTM
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-opaleye-management-inc-purchases-new-position-in-verastem-inc-vstm-2026-09-11/
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
September 8, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2986433/verastem-stock-skyrockets-121-in-3-months-here-is-why?cid=cs-stocknewsapi-ft-analyst_blog|price_surge_/_plunge-2986433
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
September 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260908273196/en/Verastem-Oncology-to-Unveil-New-Clinical-Data-Highlighting-the-Best-in-Class-Potential-of-VS-7375-an-Oral-KRAS-G12D-ONOFF-Inhibitor-Across-Pancreatic-Lung-and-Colorectal-Cancers/
Verastem (NASDAQ:VSTM) Stock Rating Upgraded by Wall Street Zen
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-verastem-nasdaq-vstm-stock-rating-upgraded-by-wall-street-zen-2026-09-05/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Close-up of a carbon fiber surface bearing the AV logo and a camera sensor.
AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone Opportunity
By Ryan Hasson | September 3, 2026
Autonomous military drone with AV-style logo on the nose sitting on a runway, representing AeroVironment and the defense drone industry.
AeroVironment's Record Backlog and Earnings Beat Fuel Recovery Case
By Thomas Hughes | September 10, 2026
Laptop displaying a candlestick stock price chart on a desk with autumn leaves and the word September overlaid.
5 Stocks to Buy in September Before Wall Street Catches On
By Thomas Hughes | August 26, 2026
Silver XPeng electric vehicle displayed in a dark showroom beneath an illuminated XPeng logo and wordmark.
XPeng’s Top Secret AI Robotics Program Outshines EV Woes
By Jeffrey Neal Johnson | August 25, 2026
Three military surveillance drones fly near a mobile radar unit at an airfield during sunset.
3 Defense Stocks Riding the High-Energy Laser Boom
By Nathan Reiff | September 15, 2026
Disc Medicine stock logo

Disc Medicine NASDAQ:IRON

$68.48 -0.01 (-0.01%)
Closing price 09/22/2026 04:00 PM Eastern
Extended Trading
$68.47 -0.01 (-0.01%)
As of 09/22/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$23.32 +0.74 (+3.28%)
Closing price 09/22/2026 04:00 PM Eastern
Extended Trading
$24.12 +0.80 (+3.45%)
As of 09/22/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Nurix Therapeutics stock logo

Nurix Therapeutics NASDAQ:NRIX

$25.67 +0.26 (+1.02%)
Closing price 09/22/2026 04:00 PM Eastern
Extended Trading
$25.68 +0.01 (+0.06%)
As of 09/22/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Verastem stock logo

Verastem NASDAQ:VSTM

$8.37 +0.38 (+4.76%)
Closing price 09/22/2026 04:00 PM Eastern
Extended Trading
$8.36 -0.01 (-0.11%)
As of 09/22/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas